Meeting NewsVideo

VIDEO: Reloxaliase may reduce oxalate burden in patients with enteric hyperoxaluria, CKD

WASHINGTON — At ASN Kidney Week, Allena Pharmaceuticals reported positive results from two trials that evaluated reloxaliase in reducing urinary oxalate in patients with enteric hyperoxaluria, as well as in reducing plasma oxalate in those who also have advanced chronic kidney disease.

In a Healio Nephrology video exclusive, Annamaria Kausz, MD, chief medical officer for Allena Pharmaceuticals, provided insight into these findings.

“Patients with enteric hyperoxaluria are at high risk for developing kidney stones, as well as chronic kidney disease,” she said. “To date, there are no approved pharmacologic therapies to target this patient population … The results of URIROX-1 are very encouraging to us at Allena.”

WASHINGTON — At ASN Kidney Week, Allena Pharmaceuticals reported positive results from two trials that evaluated reloxaliase in reducing urinary oxalate in patients with enteric hyperoxaluria, as well as in reducing plasma oxalate in those who also have advanced chronic kidney disease.

In a Healio Nephrology video exclusive, Annamaria Kausz, MD, chief medical officer for Allena Pharmaceuticals, provided insight into these findings.

“Patients with enteric hyperoxaluria are at high risk for developing kidney stones, as well as chronic kidney disease,” she said. “To date, there are no approved pharmacologic therapies to target this patient population … The results of URIROX-1 are very encouraging to us at Allena.”

    See more from American Society of Nephrology Annual Meeting